Compare TG Therapeutics Inc (TGTX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Global X Uranium ETF — how do they compare? TG Therapeutics Inc trades at $48.93 (market cap $7.58B), while Global X Uranium ETF trades at $45.23. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | URA | |
|---|---|---|
Market Cap | $7.58B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $59.06 | $61.81 |
52-Week Low | $26.94 | $36.45 |
Enterprise Value | $7.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
URA, the Global X Uranium ETF, trades at $45.20, up 1.85% on the day, with a bullish technical signal from moving averages and strong buying pressure indicated by ADX. The ETF benefits from positive sentiment around nuclear energy demand driven by AI power needs and government support, including a recent $17.5 billion U.S. loan commitment for new reactors. However, RSI levels suggest potential overbought conditions near-term.
The outlook for URA is positive due to structural tailwinds in nuclear energy, but risks include ETF expense ratios and uranium price volatility. Investor sentiment is bolstered by index expansions and geopolitical deals, yet the fund lacks traditional valuation metrics as it holds diversified uranium-related equities rather than operating as a single company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
